Primary nocturnal enuresis (PNE) is a distressing condition that can have a significant impact on a young person’s behaviour and emotional and social well-being.1,2 DesmoMelt is well accepted by children of various ages and facilitates early intervention,3 providing an effective and convenient solution to primary nocturnal enuresis and helping children and families return to a normal life.
DesmoMelt prescribing information can be downloaded via the icon. Alternatively the SmPC can be accessed via the EMC website.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Ferring Pharmaceuticals Ltd.
Tel: 0800 111 4126, Email: mailto:firstname.lastname@example.org
DesmoMelt is licensed for the treatment of PNE in children and adults aged 5 to 654 and is the preferred paediatric formulation in children aged 5–11 years.3 DesmoMelt is associated with a significant improvement in diuresis rate and numerically higher compliance compared with the tablet.3,5
Primary nocturnal enuresis (PNE) is a distressing condition that can have a significant impact on a young person’s behaviour and emotional and social well-being.1,2
DesmoMelt is a sublingual oral lyophilisate formulation of desmopressin, licensed for the treatment of primary nocturnal enuresis (PNE) in children and adults aged 5 to 65.4
Desmopressin is recommended by NICE as an initial treatment strategy for bedwetting in children from the age of 5 years old, under certain circumstances.6
DesmoMelt – desmopressin that melts under the tongue without the need for water3
Due to its formulation, DesmoMelt is associated with numerically a higher compliance level vs. the tablet and retains similar levels of efficacy and safety at lower dosing levels.3
Watch this short clip which shows how quickly the sublingual formulation gets to work versus the tablet formulation.